|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the combination of DAI and TPT showed a stronger inhibitory effect (P < 0.01) on tumor growth in both MCF7 and MCF7/ADR xenograft models than the 9 mg/kg TPT monotherapy group.
|
31408695 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The MCF-7/ADR xenograft tumor model also revealed that in comparison with DOX, the NPs exhibited satisfactory performance in promoting apoptosis of tumor cells and achieved high therapeutic outcomes for MDR tumors.
|
31141733 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, 32c showed a significant tumor growth inhibition (antitumor rate = 63.98%, p < 0.05) in the resistant MCF-7/ADR xenograft model without any obvious body weight changes and abnormal behaviors.
|
30251407 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, the dual-drug-loaded liposomes increased tumor targeting and intratumoral blood oxygen saturation, which suggested that the tumor reoxygenation effect of MET facilitated the exertion of its synergistic activity with DOX against MCF7/ADR xenografts.
|
31095914 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared to non-GA modified carriers, GNPs-P-Dox-GA exhibited increased cellular uptake nearly 4-fold and mitochondria distribution 8.8-fold, and increased ROS production level nearly 3-fold, significantly decreased efflux rate (55% compared with Dox group) in drug resistant HepG2/ADR cells, and then led to improved <i>in vitro</i> antitumor efficiency in HepG2/ADR cells (IC<sub>50</sub> only 19.5% of unmodified ones) as well as exciting <i>in vivo</i> antitumor efficiency on HepG2/ADR heterotopic tumor nude mice (1.75-fold higher tumor growth inhibition rate than free drug).
|
31465208 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo research showed that Pep-SS-NPs significantly enhanced antitumor efficacy against MCF-7/ADR xenograft tumors compared to the control groups.
|
31495855 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Besides, in vivo experiments further demonstrated that co-encapsulated nanoparticles had higher DOX accumulation and superiorer tumor growth inhibition (TGI 82.9%) than free drugs or single-drug-loaded nanoparticles on MCF-7/ADR bearing-mice.
|
31132609 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To effectively reverse MDR in tumor treatments, a new pH-sensitive nano drug delivery system (NDDS) composed of mesoporous silica nanoparticles (MSNs) and d-a-tocopheryl poly-ethylene glycol 1000 succinate (TPGS) copolymers was synthesized to deliver doxorubicin (DOX) into drug-resistant breast cancer cell line (MCF-7/ADR).
|
29519418 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In accordance with the in vitro results, DOX-loaded MPEG-PLH-VES/B NPs showed the strongest inhibitory effect against the MCF-7/ADR xenografted tumors with negligible systemic toxicity, as evidenced by the histological analysis and change of body weight.
|
29618203 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PLG-g-mPEG-PPT shows significantly decreased hemolytic activity, greatly improved maximum tolerated dose and remarkably enhanced antitumor efficacy against MCF-7/ADR xenograft tumors as compared to free PPT.
|
29694920 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, the prodrug PMs showed enhanced efficacy for inhibiting tumor growth in S180 sarcoma tumor model and in drug-resistant tumor model MCF-7/ADR and preventing lung metastasis in 4T1 in situ breast cancer model.
|
29958912 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Then the effects of PPZ pretreatment and/or ADR were compared by determining the tumor size, tumor weight and nude mice weight.
|
30349304 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Afterwards, MCF-7/ADR xenografts tumor model was established in nude mice.
|
29719378 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the codelivery of anti-miR21 and NLS-Dox by HMNs showed synergistic antiproliferative effects in MCF7/ADR-bearing nude mice, and was more effective in tumor inhibition than other drug formulations.
|
28115844 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, significantly enhanced tumor growth inhibition was observed in nude mice bearing A549/ADR xenograft tumors after the administration of AG-PEG-SS-PLA/PTX nanomicelles via tail injection.
|
29179722 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In accordance with the in vitro results, AT-M and <sub>endo</sub>E-M demonstrated the strongest inhibition on the MCF-7 and MCF-7/ADR xenografted tumor, respectively.
|
28243082 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dox-loaded RPN significantly enhances the therapeutic efficacy (92% inhibition of tumor growth) against MCF-7/ADR xenograft tumor in mice, while Dox-loaded PM only inhibits the tumor growth by 36%.
|
27943612 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied the specific activity and expression of AKR1B1 and AKR1B10 in breast non tumor and tumor tissues and in the blood.
|
27855345 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our study identifies AKR1B1 as a key modulator of tumor aggressiveness and suggests that pharmacologic inhibition of AKR1B1 has the potential to become a valuable therapeutic strategy for BLBC.
|
28270406 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of anti-tumor activity was achieved in an MCF-7/ADR multicellular tumor spheroid model and transgenic zebrafish model.
|
27250110 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further in vivo efficacy evaluation in multidrug-resistant human erythroleukemia K562/ADR xenograft model revealed that i.v. administration of curcumin-loaded mPEG-PCL-Phe(Boc) micelles significantly delayed tumor growth, which was attributed to the improved stability of curcumin in the bloodstream and increased systemic bioavailability.
|
28199114 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The frequency of AKR1B10-positive GC specimens was higher in patients with tumor size <5 cm, no lymph node metastasis, no distant metastasis and lower tumor stages The mean survival time for patients in the AKR1B10-positive group was significantly higher compared with the AKR1B1-negative group.
|
24406159 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we have investigated how AR inhibition prevents tumour growth via regulation of microRNA (miR)-21-mediated programmed cell death 4 (PDCD4) expression in colon cancer cells in in vitro and in vivo.
|
23827854 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, inhibition of AR also prevented the tumor growth of human colon cancer cells in nude mouse xenografts.
|
20354121 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Suppressing MRP1 efflux using the inhibitor MK-571 and small interfering RNA in cell lines with intrinsic and acquired MRP1 overexpression (A549 and HL-60/ADR) and in cell lines stably transduced with MRP1 (MCF7/MRP1) increased intracellular drug accumulation and increased tumor cell sensitivity to geldanamycin analogues.
|
19067123 |
2009 |